Readers and Tweeters Decry Medical Billing Errors, Price-Gouging, and Barriers to Benefits
KHN gives readers a chance to comment on a recent batch of stories.
Reporter Follows Up on ‘Cancer Moonshot’ Progress and the Bias in Digital Health Records
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
For Nursing Home Patients, Breast Cancer Surgery May Do More Harm Than Good
A new study of 6,000 older patients shows little gain from surgeries for breast cancer.
Cascade of Costs Could Push New Gene Therapy Above $1 Million Per Patient
The costs of using a new class of cancer treatments include far more than the drug鈥檚 sticker price.
“驴Cu谩nto tiempo me queda, doctor?” Por qu茅 muchos pacientes con c谩ncer no obtienen respuestas
Muchas veces los pacientes con c谩ncer no reciben respuestas adecuadas a preguntas cr铆ticas, entre ellas, la m谩s crucial y universal de todas.
鈥楬ow Long Have I Got, Doc?鈥 Why Many Cancer Patients Don鈥檛 Have Answers
Due to poor doctor-patient communication, most people with advanced cancer don鈥檛 know enough about their disease to make vital decisions.
Widespread Hype Gives False Hope To Many Cancer Patients
Doctors and drug developers have a stake in making cancer treatments seem better than they really are.
Sticker Shock Forces Thousands Of Cancer Patients To Skip Drugs, Skimp On Treatment
A growing number of patients fail to fill prescriptions because the cost of cancer drugs is too high.
Dozens Of New Cancer Drugs Do Little To Improve Survival, Frustrating Patients
The FDA has approved dozens of new cancer medications in recent years, but few offer the benefits that patients seek.
Nuevas drogas contra el c谩ncer, 驴ayudan a vivir m谩s?
Empujados por defensores de pacientes que quieren acceso temprano a los medicamentos, la FDA ha aprobado una r谩faga de drogas oncol贸gicas en los 煤ltimos a帽os, Pero pocas de estas drogas han permitido a pacientes con una esperanza de vida limitada, vivir por a帽os.
